AhmadMohammad AminMasriMD

PubMed

• Long-Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER-OLE Study.
  Amy J Sehnert, Ganesh Balaratnam, Ashish Shah, Shawna Fox, Ahmad Masri, Steven J Lester, John C Stendahl, Sheila M Hegde, Andrew Wang> ;Journal of the American Heart Association. 2024 Apr 16
• Safety and Efficacy of Metabolic Modulation With Ninerafaxstat in Patients With Nonobstructive Hypertrophic Cardiomyopathy.
  Martin S Maron, Masliza Mahmod, Azlan Helmy Abd Samat, Lubna Choudhury, Daniele Massera, Dermot M J Phelan, Sharon Cresci, Matthew W Martinez, Ahmad Masri, Theodore P ...> ;Journal of the American College of Cardiology. 2024 Apr 1
• Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4.
  Ahmad Masri, Mark V Sherrid, Theodore P Abraham, Lubna Choudhury, Pablo Garcia-Pavia, Christopher M Kramer, Roberto Barriales-Villa, Anjali T Owens, Florian Rader, She...> ;Journal of Cardiac Failure. 2024 Mar 15
• 1 citations
  Stratifying Disease Progression in Patients With Cardiac ATTR Amyloidosis.
  Adam Ioannou, Francesco Cappelli, Michele Emdin, Christian Nitsche, Simone Longhi, Ahmad Masri, Alberto Cipriani, Mattia Zampieri, Federica Colio, Michael Poledniczek,...> ;Journal of the American College of Cardiology. 2024 Mar 1
• The Revolution of Cardiac Myosin Inhibitors in Patients With Hypertrophic Cardiomyopathy.
  Rebecca Haraf, Ahmad Masri, Hany Habib> ;The Canadian Journal of Cardiology. 2024 Jan 26
• Impact of concomitant surgical interventions on outcomes of septal myectomy in obstructive hypertrophic cardiomyopathy.
  Ahmed M Altibi, Abharika Sapru, Fares Ghanem, Yuanzi Zhao, Ahmad Alani, Joaquin Cigarroa, Babak Nazer, Howard K Song, Ahmad Masri> ;International Journal of Cardiology. 2024 Apr 1
• 5 citations
  Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort.
  Rader, F., Oręziak, A., Choudhury, L., Saberi, S., Fermin, D., Wheeler, M., Abraham, T., Garcia-Pavia, P., Zwas, D., Masri, A., Owens, A., Hegde, S., Seidler, T., Fox,...> ;JACC. Heart Failure. 2024 Jan 1
• Treatment response assessment in transthyretin-related cardiac amyloidosis: an emerging clinical indication of bone-seeking radiopharmaceuticals?
  Gheysens, O., Treglia, G., Hyafil, F., Masri, A., Dorbala, S.> ;European Journal of Nuclear Medicine and Molecular Imaging. 2024 Feb 1
• 1 citations
  Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis.
  Masri, A., Maurer, M., Claggett, B., Kulac, I., Waddington Cruz, M., Conceição, I., Weiler, M., Berk, J., Gertz, M., Gillmore, J., Rush, S., Chen, J., Zhou, W., Kwoh, ...> ;Journal of Cardiac Failure. 2023 Dec 7
• EstimATTR: A Simplified, Machine-Learning-Based Tool to Predict the Risk of Wild-Type Transthyretin Amyloid Cardiomyopathy.
  Castaño, A., Huda, A., Calambur, V., Bruno, M., Schumacher, J., Emir, B., Isherwood, C., Heitner, S., Masri, A., Shah, S.> ;Journal of Cardiac Failure. 2023 Dec 7
• Correction to: Differentiating Cardiac Troponin Levels During Cardiac Myosin Inhibition or Cardiac Myosin Activation Treatments: Drug Effect or the Canary in the Coal ...
  Matthew M Y Lee, Ahmad Masri> ;Current Heart Failure Reports. 2024 Feb 1
• 1 citations
  Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study Design.
  Caroline J Coats, Martin S Maron, Theodore P Abraham, Iacopo Olivotto, Matthew M Y Lee, Michael Arad, Nuno Cardim, Chang-Sheng Ma, Lubna Choudhury, Hans-Dirk Düngen, P...> ;JACC. Heart Failure. 2024 Jan 1
• 1 citations
  Differentiating Cardiac Troponin Levels During Cardiac Myosin Inhibition or Cardiac Myosin Activation Treatments: Drug Effect or the Canary in the Coal Mine?
  Matthew M Y Lee, Ahmad Masri> ;Current Heart Failure Reports. 2023 Dec 1
• 12 citations
  Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy.
  Brannagan, T. H., Teresa Coelho, Wilson Marques Jr, Noel R Dasgupta, Chi-Chao Chao, Yesim Parman, Marcondes Cavalcante França Jr, Yuh-Cherng Guo, Jonas Wixner, Long-Su...> ;JAMA. 2023 Oct 17
• Patient-Level Artificial Intelligence-Enhanced Electrocardiography in Hypertrophic Cardiomyopathy: Longitudinal Treatment and Clinical Biomarker Correlations.
  Siontis, K., Abreau, S., Attia, Z., Barrios, J., Dewland, T., Agarwal, P., Balasubramanyam, A., Li, Y., Lester, S., Masri, A., Wang, A., Sehnert, A., Edelberg, J., Abr...> ;JACC. Advances. 2023 Oct 1
• Comparative Outcomes of a Transthyretin Amyloid Cardiomyopathy Cohort Versus Patients With Heart Failure With Preserved Ejection Fraction Enrolled in the TOPCAT Trial.
  Morris M Kim, Mark Prasad, Yunwoo Burton, Clinton M Kolseth, Yuanzi Zhao, Pranav Chandrashekar, Babak Nazer, Ahmad Masri> ;Journal of the American Heart Association. 2023 Aug 1
• 1 citations
  Efficacy and safety of dofetilide and sotalol in patients with hypertrophic cardiomyopathy.
  Chris Chen, Mallika Lal, Yunwoo Burton, Hongya Chen, Eric Stecker, Ahmad Masri, Babak Nazer> ;Communications Medicine. 2023 Jul 19
• 6 citations
  Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3.
  Anjali T Owens, Ahmad Masri, Theodore P Abraham, Lubna Choudhury, Florian Rader, John D Symanski, Aslan T Turer, Timothy C Wong, Albree Tower-Rader, Caroline J Coats, ...> ;Journal of Cardiac Failure. 2023 Nov 1
• 9 citations
  Hospital Procedural Volume and Clinical Outcomes Following Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy.
  Ahmed M Altibi, Yuanzi Zhao, Miriam Elman, Joaquin Cigarroa, Babak Nazer, Howard K Song, Ahmad Masri, Fares Ghanem> ;Journal of the American Heart Association. 2023 May 16
• Genetic Testing for Cardiomyopathies in Japan: Embarking on a Journey of Discovery.
  Ahmad Masri, Nosheen Reza> ;Journal of Cardiac Failure. 2023 May 1
• Baseline and Longitudinal Imaging of Hypertrophic Cardiomyopathy in the Era of Emerging Therapeutics.
  Ahmed Altibi, Ahmad Alani, Yuanzi Zhao, Ahmad Masri> ;Current Cardiology Reports. 2023 Jun 1
• 10 citations
  Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized Trial.
  Matthew T Wheeler, Iacopo Olivotto, Perry M Elliott, Sara Saberi, Anjali T Owens, Mathew S Maurer, Ahmad Masri, Amy J Sehnert, Jay M Edelberg, Yu-Mao Chen, Victoria Fl...> ;JAMA Cardiology. 2023 Mar 1
• Evolving epidemiology of transthyretin amyloid cardiomyopathy due to increased recognition in women.
  Mark Prasad, Morris Kim, Pranav Chandrashekar, Yuanzi Zhao, Katherine L Fischer, Babak Nazer, Ahmad Masri> ;International Journal of Cardiology. 2023 Mar 1
• 3 citations
  Targeted Screening for Transthyretin Amyloid Cardiomyopathy in Patients With Atrial Fibrillation.
  Stacey Howell, Saket Sanghai, Eric Stecker, Charles A Henrikson, Ahmad Masri, Babak Nazer, Prasad, P.> ;Circulation. 2022 Nov 29
• 2 citations
  Liver-directed drugs for transthyretin-mediated amyloidosis.
  Thomas H Brannagan 3rd, John L Berk, Julian D Gillmore, Mathew S Maurer, Márcia Waddington-Cruz, Marianna Fontana, Ahmad Masri, Laura Obici, Michela Brambatti, Brenda ...> ;Journal of the Peripheral Nervous System. 2022 Dec 1
• Join now to see all

Lectures

• Pulmonary Hypertension In Aortic and Mitral Valve Disease: Pathophysiology and Outcomes 
  2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
• The Role of Vasculature in Valvular Heart Disease 
  2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
• Case Presentation 
  2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019